2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals
Dealmakers evidently spent the fourth quarter of 2016 largely in hibernation as they waited out a big US election cycle that seemed to raise more …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
